P
Purespring Therapeutics
AAV gene therapy platform targeting chronic kidney diseases
About Purespring Therapeutics
Purespring Therapeutics is a London-based biotechnology company established in 2020 by Syncona, a life science investor, and built upon the research of founders Professor Moin Saleem and Mauro Giacca. The company is a pioneer in developing adeno-associated virus (AAV) gene therapies specifically for chronic kidney diseases, an area with significant unmet medical needs. Purespring's scientific foundation is the work of Professor Moin Saleem of the University of Bristol, a leader in pediatric renal medicine whose research has focused on the podocyte—a specialized kidney cell critical to filtration and implicated in approximately 60% of renal diseases.
The company's proprietary platform is engineered to deliver gene therapies directly to podocytes, offering the potential to halt or even reverse kidney disease by correcting defective genes or modulating protein production. This targeted approach aims to provide curative treatments for both rare monogenic and more common kidney conditions, moving beyond options like dialysis or transplantation which only manage late-stage disease. Purespring's business model is centered on the research, development, and eventual commercialization of these novel therapies. Revenue generation is anticipated through product sales and strategic partnerships within the pharmaceutical and healthcare sectors.
Purespring has secured significant funding to advance its pipeline, raising approximately $60 million in a Series A round in 2020 and $105 million in a Series B round in October 2024. This capital is being used to progress its lead candidate, PS-002 for IgA Nephropathy (IgAN), into a Phase I/II clinical trial. The company's pipeline also includes programs for other conditions, such as steroid-resistant nephrotic syndrome. Preclinical data has demonstrated the platform's ability to successfully deliver genetic material to podocytes in animal models, restoring kidney function and showing no off-target effects or safety concerns.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 56
- Open positions
- None listed
- Dealroom signal
- 73.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Spinout, Disease, DT and LS, uk is8 life sciences, UKSU, UKSU2010, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2024 | $106M | $422M | British Patient Capital · Syncona · Sofinnova Partners · Forbion Capital Partners | ↗ |
| SERIES AOther financing | Nov 2020 | $59M | $238M | Undisclosed | — |
Growth signals
Latest recorded traffic for Purespring Therapeutics is 3.6K monthly website visits, up 227.3% over the last three months. Purespring Therapeutics's team grew 1.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
AviadoBioPrecision gene therapies for neurodegenerative disorders |
London, United Kingdom | Operational | 71 | $96M | $320M |
Tay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise |
Dundee, United Kingdom | Operational | |||
IntraBioTherapies for rare and common neurodegenerative diseases |
Austin, United States | Operational | |||
ViaNautis BioPolymer nanoparticle platform for targeted intracellular genetic delivery |
Cambridge, United Kingdom | Operational | |||
| London, United Kingdom | Acquired | ||||
Z FactorTherapeutic agents for alpha-1-antitrypsin deficiency treatment |
Babraham, United Kingdom | Acquired | |||
Spur TherapeuticsGene therapies for Gaucher, Parkinson's, and cardiovascular diseases |
Stevenage, United Kingdom | Acquired | |||
MironidSmall molecule therapeutics for hereditary kidney disease |
Glasgow, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Purespring Therapeutics in the London ecosystem
The Purespring Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Sofinnova Partners
British Patient Capital
Syncona
Forbion Capital Partners
Gilde Healthcare
Other known investors1 additional known investor
University of Bristol
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Purespring Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Purespring Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









